Guardant Health (GH) revealed it is raising more capital than previously planned through an expanded public stock offering and a larger convertible notes issuance. The stock dropped nearly 9% as investors weighed the potential dilution.
See our latest analysis for Guardant Health.
Even with the recent dip following news of expanded capital raises, the momentum in Guardant Health’s share price has been remarkable. The company has posted a 204% year-to-date share price return and an even stronger one-year total shareholder return of 238%, signaling substantial investor confidence in its growth trajectory. Solid quarterly results, optimistic raised guidance, and a string of product milestones have fueled this surge, though the latest financing has led to renewed scrutiny about future dilution risks.
If you’re curious about where healthcare innovation is headed next, take a see at the wide range of companies featured in our See the full list for free..
With Guardant Health’s stock still up sharply for the year but now trading just below analyst price tarreceives, the key question is whether these latest relocates have already reflected all the expected growth, or if there is genuine value left for new investors to capture.
At a last close of $96.72, the most widely followed narrative estimates Guardant Health’s fair value at $93.82. This is a slight premium to the current price and highlights just how ambitious the growth assumptions embedded in the outsee are. This invites a closer see at the projections supporting that tarreceive.
“Analysts are assuming Guardant Health’s revenue will grow by 22.5% annually over the next 3 years. Analysts are not forecasting that Guardant Health will become profitable in next 3 years. To represent the Analyst Price Tarreceive as a Future PE Valuation we will estimate Guardant Health’s profit margin will increase from -49.9% to the average US Healthcare indusattempt of 5.4% in 3 years.”
Want to uncover what’s fueling such a premium valuation? There’s an aggressive growth story here and a dramatic profit turnaround expectation. Achieving it would require surpassing today’s reality by a wide margin. Click through for the quantitative details that set this narrative apart.
Result: Fair Value of $93.82 (OVERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, persistent high spfinishing and uncertainty around broad payer adoption could still pose real risks to Guardant Health’s optimistic growth scenario.
